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Abstract
Background: This study reports on the effects of botulinum toxin A (BoNT-A) injections in the upper extremity (UE)
in children with unilateral Cerebral Palsy (uCP) combined with bimanual task-oriented therapy (BITT) or either
treatment modality performed separately. Bimanual activities were measured with the Assisting Hand Assessment
(AHA), the ABILHand-Kids questionnaire (AK), the Observational Skills Assessment Score (OSAS). Goal achievement
was measured with Goal Attainment Scaling (GAS), using blind video assessment, and the Canadian Occupational
Performance Measure (COPM).
Methods: Thirty-five children, mean age 7.14 years (SD 2.63), 11 Manual Ability Classification Score (MACS) I, 15
MACS II and 9 MACS III, participated. The trial started with four study groups: BoNT-A-only (n = 5), BITT-only (n = 11),
BoNT-A + BITT (n = 13), and control (n = 6). Twenty-two children were randomised, 13 children received their
parents’ preferred treatment: BoNT-A + BITT or BITT-only. Three comparisons were analysed: BITT (BoNT-A + BITT and
BITT-only; n = 24) versus no BITT (BoNT-A-only and control; n = 11), BoNT-A (BoNT-A-only and BoNT-A + BITT; n = 18)
versus no BoNT-A (BITT-only and control; n = 17), and the additional effect of BoNT-A (BoNT-A + BITT versus BITT-only).
Follow-up time: 24 weeks.
Results: No significant differences between the groups were found on the AHA. The amount of use of both hands on
the OSAS was significantly better in the BoNT-A group in the beading and sandwich-making task. The BoNT-A group
also showed significant improvement in the quality scores of the OSAS: the wrist position during grasping and holding,
especially in the younger children. The BITT group improved significantly on the AK and significantly more on the
performance and satisfaction scores of the COPM at 12 and 24 weeks regarding several goals. BoNT-A showed a
significant negative effect at 12 and 24 weeks in the most important goal. BITT, more than BoNT-A + BITT, showed
positive effects on the GAS score at 12 (significant), 18 and 24 weeks.
Conclusions: BoNT-A has a positive effect on quality of movement and amount of use of the affected UE during the
3 months’ working time. BoNT-A has no additional effect on bimanual performance and goal achievement. BITT has a
positive effect on goal achievement and bimanual performance, even up to 6 weeks after therapy had stopped.
Trial registration: Current Controlled Trials ISRCTN69541857.
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Background
According to the Cochrane review [1], the combination
of botulinum toxin A (BoNT-A) in the upper extremity
(UE) and intensive physiotherapy(PT)/occupational ther-
apy(OT) is more effective than intensive therapy alone
in improving the activity level of the International Clas-
sification of Functioning (ICF, www.who.int/entity/classi-
fications/icf/en/) and in goal achievement in children
with unilateral spastic Cerebral Palsy (uCP). Assess-
ments used to measure effects at the activity level in the
studies in this review are the Melbourne Assessment of
Unilateral Upper Limb Function (MUUL) [2], the Qual-
ity of Upper Extremities Skills Test (QUEST) [3] and the
Pediatric Disability Inventory (PEDI) [4]. Goal achieve-
ment was measured with Goal Attainment Scaling
(GAS) [5] and the Canadian Occupational Performance
Measure (COPM) [6].
Although the studies themselves reported no signifi-
cant differences on the MUUL and limited effects on the
QUEST, a meta analysis of the pooled data in this review
[1] showed slight positive effects on both tests 3 months
after injection of BoNT-A, which had disappeared at
6 months. On the PEDI functional skills score almost no
effect was found. There were clear positive effects on
GAS and limited positive effects on the COPM con-
cluded. Olesch et al. studied young children (mean age
3 years 8 months) with uCP and found no significant
differences on the QUEST between repeated BoNT-A +
OT and OT alone. However, they did find positive effects
on GAS of BoNT-A +OT [7]. The way GAS was per-
formed in these studies (scoring by parents or therapists)
had subjective elements. This should be taken into ac-
count, while interpreting these results.
Also, in a more recent review evaluating upper limb
therapies for uCP there was a modest supplementary ef-
fect of BoNT-A as an adjunct to OT to improve unilat-
eral capacity, quality of movement, with the MUUL and
the QUEST, and a clear positive effect on achieving indi-
vidualised treatment outcomes [8]. In this review in only
one study looking at the effect of BoNT-A on strength
in children receiving resistance training, the assisting
hand assessment (AHA) was used to measure bimanual
performance [9].
OT after BoNT-A, modified constraint induced move-
ment therapy (mCIMT), bimanual intensive therapy
(BIMT) and goal-directed and context-focused therapies
are considered to be evidence-based effective improving
UE activities [8, 10]. After BoNT-A, mCIMT and bi-
manual OT (BOT) each consisting of 16 one-hour ther-
apy sessions during 6 weeks both with home therapy
elements, were equally effective in young children with
uCP, although in hindsight the home programme inten-
sity in the BOT group was significantly less [11]. In this
study and in several studies reporting effects of CIMT
and/or BIMT, they used the AHA, a reliable, responsive
tool to measure the effective use of the assisting hand in
bimanual performance [12, 13]. With the AHA, in sev-
eral studies comparing the effects of two forms of inten-
sive therapy currently often used in uCP, CIMT and
BIMT, no difference between these treatments could be
demonstrated [14–16].
At the start of our study, there were no studies meas-
uring the effect of (additional) BoNT-A on bimanual
performance. Because we considered this effect, the ef-
fective use of the affected hand in bimanual play and
self-care, of utmost importance, we chose the AHA as
main outcome measurement in this study.
BoNT-A has a clear effect on tone reduction [1, 17],
influencing movement fluency. As fluency corresponds
with quality of use of the affected hand, measuring this
aspect, i.e., the capacity of the affected hand as an assist-
ing hand in bimanual activities, is necessary in our opin-
ion. For this, the Observational Skills Assessment Score
(OSAS) was developed and tested for its clinimetric prop-
erties. It appeared to be an appropriate instrument [18].
Therefore, in the present study, we investigated the ef-
fects of BoNT-A injections in the UE combined with bi-
manual task-oriented therapy (BITT) or either treatment
modality performed separately on the ICF activity level,
on bimanual performance, measured with the AHA and
the ABILHAND-Kids questionnaire (AK) [19], on the
amount of use and capacity of the assisting hand with
the OSAS, and on goal achieving, measured with GAS
(scored blindly on video recordings) and the COPM.
Methods
Design
This study, called BoBiVa (Botuline toxine Bimanuele
Vaardigheden), was designed as a multicentre rando-
mised controlled trial on the effect of BoNT-A injections
combined with bimanual task-oriented therapy (BITT),
or either separately, in children with uCP on UE func-
tions and skills. The trial was registered at the ISRCTN
site: http://www.controlled-trials.com/ISRCTN69541857.
The METC Atrium-Orbis-Zuyd (ref: 06-p-33) and the
Dutch CCMO (ref: NL12005.096.06) provided medical eth-
ics approval. The parents gave their informed consent for
their children to participate in the measurements and ther-
apies of this study. Initially, besides Adelante/Maastricht
University Medical Centre, two other centres, VUMC in
Amsterdam and UMC St. Radboud in Nijmegen, partici-
pated in this trial. Here, the BoNT-A injections were given.
Due to disappointing patient enrolment, other centres, in
which the BITT programme was performed, joined later.
These recruitment problems also led to a change in study
design: with approval of the METC this became a clinical
study, as is further mentioned in the ‘Randomisation’ sec-
tion. In this paper, the results at the ICF-activity level are
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reported. Originally we wanted to use a factorial design to
determine the effects of BoNT-A, BITT, and the additional
effect of BoNT-A to BITT (Table 1). As far as possible, the
CONSORT guidelines for reporting parallel group rando-
mised trials were followed [20].
Participants
Children with spastic uCP, aged 2.5 to 12 years, Manual
Ability Classification System (MACS) [21] levels I-III,
Zancolli hand impairment grade I to IIB [22], who were
mentally able to perform the measurements and attend
the therapy programme, were considered eligible for in-
clusion. The study excluded children without active
hand function (Zancolli III), severe structural contrac-
tures (elbow extension deficit more than 20° and/or su-
pination deficit more than 45° and/or wrist extension
deficit more than 30°) and children who had undergone
a treatment of the affected hand (BoNT-A injections less
than 9 months before, or hand surgery).
Therapy programme
The BITT programme consisted of half an hour of PT
and one hour of OT, 2 times a week, for 12 weeks. Chil-
dren in the outpatient clinic had the PT and OT (1 ½ h)
after each other, 2 times a week. Children who were at
the special school had the therapy during school days.
At the start, bimanual goals were set using the COPM
[6]. Examples of goals that were being targeted in the
therapy are: pulling up trousers and closing the button,
cutting paper with scissors, pulling apart LEGO bricks,
tying shoelaces, closing the zip of a jacket. These goal-
directed activities were practiced as much as possible in
the child’s relevant context. The programme was indi-
vidually tailored to the child based on a task analysis of
the selected goals performed at the start of the treatment
and was based on principles of motor learning, strength
training and/or improving range of motion (ROM).
When weakness was the main problem in closing the
button of a pair of jeans, this was trained by asking the
child to pull up his trousers and then close the button
several times, starting with wider trousers and an easier
clasp. When ROM was a problem and the finger flexors
were shortened, the children had to wear a finger flexor
stretching night splint. Also day splints facilitating hand
function were used. Additionally, parents were asked to
stimulate their child to practice these goal-directed
dressing and playing activities every day in a home-
exercise programme. They practiced these activities
several times a day during grooming and while playing.
Parents reported that during the day they spent 40 to
60 min practising these goals (56–84 h of exercise in
total). All therapists of the participating centres were
trained in this special goal-directed, task-specific bimanual
therapy. ER and AD trained the therapists to perform the
BITT programme during a 6 h training course. During the
BITT programme, these therapists were coached by AD.
Feedback was given on their task analysis using video re-
cordings of the child performing his/her individual goal.
The children in the BoNT-A-only and control group con-
tinued their usual therapy with a maximum frequency of
1 h a week. We requested their therapists not to work at
improving bimanual goals. The physiotherapists of the
children in these treatment groups were unaware of the
goal setting.
BoNT-A injection technique and dosage
The most spastic muscles hampering function and bi-
manual activities were injected once in both the BoNT-
A treatment groups; in the BoNT-A + BITT group, the
BoNT-A was injected 4 days to a maximum of 2 weeks
before the start of the BITT programme. Based on a
video of the child performing his or her most important
goal and on UE spasticity measurements, the three phy-
sicians of the initial participating centres decided during
teleconferencing which muscle had to be treated and in
what dose. Dysport® (Ipsen) was used with dilution 25
U/0.1 ml and with a dose 3 times the dose of Botox®
(Allergan), 6–9 U/kg body weight for muscles above the
elbow and 3–6 U/kg body weight for muscles in the
forearm, limited to no more than 150 units (0.6 ml) at
one injection site. In the intrinsic thumb muscles, the
maximum dose was 50 U per muscle; mostly 25 U per
muscle was injected. The total maximum Dysport® dose
was 1000 U per child per session [23]. The injections
took place under general anaesthesia in the day care de-
partment of the three initially participating centres. The
muscles that had to be injected were located by electro-
stimulation; the BoNT-A was injected with a special
Teflon® coated needle. The most frequently injected mus-
cles were the adductor pollicis, flexor carpi ulnaris
and radialis and pronator teres. For dose and which
muscle was injected see our publication of the effect
of BoNT-A and/or BITT on upper extremity func-
tions [17], or Additional file 1.
Outcome measures
Two baseline measurement sessions with a maximum of
2 weeks in between, and four follow up sessions at 6, 12,
18 and 24 weeks after BoNT-A/start BITT were per-
formed. The AHA, the primary outcome measure, was
Table 1 Factorial study design
BoNT-A yes BoNT-A no
BITT yes BoNT-A + BITT (n = 13) BITT-only (n = 11) 24
BITT no BoNT-A-only (n = 5) Control (n = 6) 11
18 17
BoNT-A botulinum toxin A. BITT bimanual task-oriented therapy
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administered at the second baseline session and at 12
and 24 weeks. The AK was taken at the first baseline
session and all follow-up sessions. Both the AHA (a
video assessment) and the AK (a questionnaire) were per-
formed to measure effectiveness of use of the affected
hand (AH) in bimanual performance. To measure amount
and quality of use of the AH i.e., capacity, the OSAS [18]
was administered. The AHA and the OSAS were adminis-
tered by a certified, experienced occupational therapist
(OTst). With the COPM, which was administered at the
first baseline session, 3 goals in which bimanual hand use
was needed were determined. Evaluation of these goals
with the COPM took place at 12 and 24 weeks. The most
important problem that emerged from the COPM was
video recorded at the second baseline measurement ses-
sion. Watching this video, goal attainment scaling (GAS)
was performed by the first author (LS) and an experienced
OTst (AD). A 6-point scale was used with 0 representing
the expected level of success, 2 clearly more than expected
and −3 worse than before [5]. At all the other measure-
ment sessions, new video recordings of this main goal
were made. Afterwards these GAS videotapes and those of
the AHA and OSAS were renamed and scored by trained
assessors (PTsts and OTsts). These assessors were not
involved in the treatment and unaware at which time
session the video was taken, so blinding was guaran-
teed. The AHA score was converted to the AHA 0–100
units score. Additionally, measurements at function
level of the ICF were performed. These results have
been reported earlier [17].
Sample size
Power analysis was done on the AHA, as this was the
main outcome measurement of the BoBiVa study at the
ICF activity level. At the start of this study, the study of
Eliasson [24] was the only known study that used the
AHA as an evaluative measurement. We assumed that
the difference between groups (mCIMT and control) as
found by Eliasson (mean change for the treatment group
1.23 (SD 1.04) and for the control group 0.24 (SD 0.85))
was the minimum clinically relevant difference to be de-
tected in our study. Using the same variation, a two-
sided alpha of 0.05 and a beta of 0.10 (i.e., power of
90 %), a minimum of 50 children in total were needed to
detect the main effects of the treatment comparisons
(effect of BoNT-A, BITT or BoNT-A + BITT) on daily
hand use.
Randomisation
The trial started with a factorial design in 2008. There
were 4 study groups: 1) BoNT-A-only, 2) BITT-only, 3)
BoNT-A + BITT and 4) control group (Table 1). To
improve comparability of the groups, randomisation
into the four treatment groups took place after pre-
stratification for centre and age group: 2.5–6 and 7–
12 years. Randomisation was done after the two base-
line measurements and before start of the treatment.
Using opaque envelopes ensured allocation conceal-
ment. An independent researcher generated random
allocation sequence. LS and JB enrolled participants.
YJ assigned participants to the intervention by hand-
ing out the opaque envelopes. Because of recruitment
problems, we abandoned the randomisation into 4 groups
after official approval of the medical ethics committee.
This adaptation was necessary because many parents did
not want their child to participate, because they either had
a strong preference for or aversion to BoNT-A treatment.
Also, they considered the risk of allocation of their child
to either the control or the BoNT-A-only group to be too
high. From March 2010 on, the children were only allo-
cated to the BoNT-A + BITT or the BITT-only group.
The scientific importance of random allocation was dis-
cussed with the parents. If the parents agreed, the children
were randomised; otherwise, their child was allocated to
the group of their preference. As this was the choice of
the parents and not of a physician, we do not expect that
it has led to confounding by indication.
Statistical analysis
Categorical and numerical variables were presented by
number of patients (%) and by means (SD), respectively.
The longitudinal effects of bimanual therapy (BITT ver-
sus no-BITT) and BoNT-A (BoNT-A versus no-BoNT-
A) on the numerical outcome measures were assessed
using linear mixed models to correct for baseline differ-
ences and to account for the correlations between
repeated measures within the same patient and for miss-
ing data by using likelihood methods, which assume the
data to be missing at random. The fixed part of the
models included BITT (yes/no), BoNT-A (yes/no), time
(0, 6, 12, 18 and 24 weeks), BITT*time, and BoNT-
A*time. Restricted maximum likelihood estimation was
used and the covariance structure for the repeated mea-
sures (compound symmetry (CS), heterogeneous CS, first-
order autoregressive (AR1), heterogeneous AR1, Toeplitz
(TP), heterogeneous TP or unstructured) was selected
based on Akaike’s information criterion. As for the add-
itional effect of BoNT-A (BoNT-A + BITT versus BITT-
only) on the outcome measures, a similar linear mixed
model (without the variables BITT and BITT*time) was
applied to the data of the patients who received either
BITT-only or BoNT-A + BITT. For the ordinal GAS score,
the differences between the groups were assessed using
the Kruskal-Wallis test. A two-sided p-value ≤ 0.05 was
considered statistically significant. All analyses were per-
formed using IBM SPSS Statistics for Windows (Version
20.0. Armonk, NY: IBM Corp).
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Results
Patients were enrolled from January 2008 until December
2010. The last follow-up measurement took place in
September 2011. Initially, thirty-six children with uCP
were enrolled in the study. One child, who was allocated
to the BITT-only group, withdrew after the baseline mea-
surements because the participating centre had problems
organizing BITT. Therefore, a total of 35 children partici-
pated in the study. Twenty-four were born at full term, 6
at 37 weeks and 5 were born prematurely (25–35 weeks
gestation).
Twenty-two children were allocated by randomisation;
in 13 children the parents’ preference was followed
(Fig. 1) of whom nine were allocated to the BoNT-A +
BITT group and four to the BITT-only group. The par-
ents of one young child in the latter group indicated
after the baseline measurements that they were not able
to bring their child for therapy twice a week. They
agreed to let him perform the measurements only, so
the child was allocated to the control group. Two chil-
dren who were randomly assigned to the control group
missed the outcome measurements of week 6, 18 and
24. One because she underwent surgery to improve
walking; the parents of the other child were no longer
willing to cooperate with the measurements. Their base-
line and 12 week measurement results were analysed.
We used a registration form for Serious Adverse
Events (SAE’s) and Suspected Unexpected Serious Ad-
verse Reactions (SUSAR’s), but no adverse reactions
were reported.
In Table 2, characteristics and outcome measures at
baseline of all children and treatment groups are
depicted. The children in the control group and less in
the BoNT-A-only group were clearly younger. Hand
function impairment (Zancolli grade) was worst in the
control group and in the BoNT-A-only group bimanual
performance i.e., the MACS was worst. Children in the
control group scored relatively low on the AHA units
and the ABILHAND-Kids logit units’ score. Overall,
there were no significant differences between the groups
at baseline.
Because the OSAS has different standardised tasks for
two age groups, 2.5 to 6 and 7 to 12 years old, the base-
line values for these two age groups are given separately
in the online Additional files 2 and 3. The group sizes
were small in general. The younger children were more
equally distributed across the four treatment groups.
With a mean age of 3 years, the two young children in
the BoNT-A-only group were clearly younger than their
peers in the other treatment groups. Their performance
was clearly worse in using both hands in the OSAS
tasks. The control group contained only two children
from the older age group and one of them performed
badly on the AHA, and showed a low percentage of use
in the OSAS construction tasks.
In Tables 3 - 6, the results of three comparisons are
presented: a) BITT (BoNT-A + BITT and BITT-only)
versus no-BITT (BoNT-A-only and control), b) BoNT-A
(BoNT-A-only and BoNT-A + BITT) versus no-BoNT-A
(BITT-only and control), and c) the additional effect of
BoNT-A, i.e., BoNT-A + BITT versus BITT-only. The
most relevant results of these comparisons will be dis-
cussed per table.
With the AHA, our primary outcome measurement,
no significant differences between the groups could be
demonstrated (Table 3). From baseline until 12 weeks, 6
children deteriorated in AHA unit score, all children
had BoNT-A injections; those who had not showed no
decline (see the online Additional file 1 with individual
AHA unit scores). Comparing BoNT-A versus no-BoNT-
A and BoNT-A + BITT versus BITT-only, the groups in
which the children did not receive BoNT-A showed a
clear improvement from 0 to 12 weeks, whereas the
BoNT-A groups did not. The children who received BITT
scored significantly better at the ABILHAND-Kids logit
units’ score at 12 and 18 weeks (BITT from 1.301 to 2.264
and 2.190 and no-BITT from 1.092 to 1.173 and 0.796);
and not significantly better at 24 weeks (BITT 2.230, no
BITT 1.114). Comparing BoNT-A versus no-BoNT-A and
BoNT-A + BITT versus BITT-only, the no-BoNT-A and
Fig. 1 Allocation flow diagram participants after 2
baseline measurements
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the BITT-only groups showed a clear improvement in the
AK logit units’ score, maximum at 12 weeks.
In the younger age group the percentage of use of
both hands of the OSAS treading beads task increased
from 69.7 % at baseline to 75.5 % at 18 and 73.1 % at
24 weeks in the BoNT-A group, which was significantly
better than in the no-BoNT-A group (decrease from
83.2 % at baseline to 79.1 % at 18 and 76.4 % at
24 weeks) (Table 4). In the older age group, BoNT-A
had a significant positive effect on the percentage of use
of both hands at 6 weeks and at 24 weeks in the
sandwich-making OSAS task (Table 5).
In Table 4, the OSAS quality of use scores of the af-
fected, assisting hand in the younger age group are
shown. There was clear improvement in the grasp wrist
and the hold wrist score at 6, 12, 18 and in the Pop-Onz
task also at 24 weeks and overall in the BoNT-A group,
comparing BoNT-A versus no-BoNT-A, and a de-
crease in the no-BoNT-A group in the beading and
the Pop-Onz tasks, resulting in significant differences
between these groups. Comparing BoNT-A + BITT to
BITT-only, there were also significant differences in
these tasks favouring BoNT-A at 6 and 12 weeks in
the Pop-Onz task.
Table 5 displays the OSAS quality of use scores of the
older children. Comparing BoNT-A to no-BoNT-A and
BoNT-A + BITT to BITT-only, the grasp wrist score was
significantly better favouring BoNT-A in the large con-
struction task at 6 weeks and the hold wrist score in the
sandwich-making task at 6 weeks and in the small con-
struction task at 6, 12 and 18 weeks and overall.
The grasp finger score of the sandwich-making task
differed significantly at 6 weeks comparing BoNT-A to
no-BoNT-A (1.18 to 1.88 versus 1.69 to 1.60, p 0.011)
and comparing BoNT-A + BITT to BITT-only (1.78 to
1.84 versus 1.76 to 1.63, p 0.020) favouring BoNT-A.
Performance and satisfaction scores of the COPM are
depicted in Table 6. In all three goals there was a signifi-
cant difference in improvement of performance and sat-
isfaction scores at 12 weeks and overall and in the
second and third goal also at 24 week satisfaction scores
in the BITT versus no-BITT comparison favouring
BITT. In the first goal the no-BoNT-A (comparing
BoNT-A versus no-BoNT-A) and the BITT-only group
(BoNT-A + BITT versus BITT-only) improved signifi-
cantly more.
In Figs. 2 and 3 the medians and ranges of the GAS
score per treatment group at 12 and 18 weeks are given.
We did not compute the GAS T score, as the GAS,
which was scored blindly on a video, was only performed
at one treatment goal, so this had no statistical implica-
tions [25]. The BITT-only group performed significantly
better at 12 weeks compared to the other groups. In the
BITT-only group, the GAS score improved from −2
Table 2 Characteristics and outcome measures at baseline total group of children
All children BoNT-A + BITT BoNT-A-only BITT-only Control All
n = 13 n = 5 n = 11 n = 6 n = 35
Age (years) mean (sd) 7.8 (2.7) 6.6 (3.5) 7.4 (2.4) 5.7 (2.0) 7.1 (2.6)
Hemi side
Hemi right n (%) 9 (69.2) 3 (60.0) 6 (54.5) 1 (16.7) 19 (54.3)
Hemi left n (%) 4 (30.8) 2 (40.0) 5 (45.5) 5 (83.3) 16 (45.7)
Zancolli grade
Zancolli I n (%) 9 (69.1) 2 (40.0) 6 (54.5) 2 (33.3) 20 (57.1)
Zancolli II A n (%) 3 (23.1) 3 (60.0) 4 (36.4) 2 (33.3) 11 (31.4)
Zancolli II B n (%) 1 (7.7) 0 (0.0) 1 (9.1) 2 (33.3) 4 (11.4)
MACS
MACS I n (%) 2 (15.4) 2 (40.0) 4 (36.4) 3 (50.0) 11 (31.4)
MACS II n (%) 7 (53.8) 1 (20.0) 4 (36.4) 3 (50.0) 15 (42.9)
MACS III n (%) 4 (30.8) 2 (40.0) 3 (27.3) 0 (0.0) 9 (25.7)
AHA
Units (SD) 56.0 (9.0) 56.4 (12.1) 59.3 (12.6) 49.5 (10.3) 56.0 (10.9)
ABILHAND-Kids
Logit units (sd) 1.205 (0.915) 1.393 (0.430) 1.418 (0.766) 0.839 (1.494) 1.236 (0.927)
COPM mean of 3 goals
Performance mean (sd) 4.2 (1.5) 3.5 (1.2) 3.4 (1.3) 3.2 (1.4) 3.7 (1.4)
Satisfaction mean (sd) 4.9 (2.1) 4.9 (1.9) 4.1 (1.5) 3.9 (1.8) 4.5 (1.8)
Mean scores and standard deviations
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Table 3 AHA units and ABILHand-Kids logits, estimated means (standard errors)
Follow-up
weeks
BITT BoNT-A BoNT-A additional effect








p-value BoNT-A + BITT BITT-only p-value
n = 24 n = 11 n = 18 n = 17 n = 13 n = 11
AHA Units (SE) p-value 0 57.5 (2.2) 52.6 (3.3) 55.0 (2.7) 55.1 (2.7) 56.0 (3.0) 59.3 (3.3)
12 59.6 (2.2) 54.2 (3.3) 0.811 55.5 (2.7) 58.3 (2.7) 0.142 56.7 (3.0) 62.7 (3.3) 0.183
24 58.8 (2.2) 56.8 (3.4) 0.135 57.5 (2.7) 57.8 (2.8) 0.895 58.1 (3.0) 59.0 (3.3) 0.251
overall 0.192 0.274 0.054
ABILHand-Kids Logit units (SE)
p -value
0 1.301 (0.25) 1.092 (0.37) 1.210 (0.31) 1.183 (0.31) 1.204 (0.33) 1.418 (0.36)
6 1.481 (0.25) 1.000 (0.39) 0.468 1.162 0.31) 1.319 (0.32) 0.589 1.238 (0.33) 1.772 (0.37) 0.457
12 2.264 (0.25) 1.173 (0.37) 0.041 1.384 (0.31) 2.054 (0.31) 0.080 1.868 (0.33) 2.672 (0.36) 0.239
18 2.190 (0.26) 0.796 (0.39) 0.016 1.297 (0.31) 1.689 (0.33) 0.341 1.859 (0.33) 2.580 (0.38) 0.340
24 2.230 (0.25) 1.114 (0.40) 0.128 1.369 (0.31) 1.976 (0.33) 0.241 1.980 (0.33) 2.470 (0.36) 0.659
overall 0.132 0.457 0.748












Table 4 Amount and Quality of use of grasp and hold wrist scores, tasks younger age group
Follow-up
weeks
BITT BoNT-A BoNT-A additional effect








p-value BoNT-A + BITT BITT-only p-value
n = 8 n = 6 n = 6 n = 8 n = 4 n = 4
OSAS percentage of use
both hands
0 80.6 (4.6) 72.4 (5.4) 69.7 (5.4) 83.2 (4.6) 76.7 (4.7) 84.5 (4.7)
6 78.6 (3.9) 68.3 (4.7) 0.662 66.7 (4.6) 80.1 (4.0) 0.980 73.1 (4.2) 84.1 (4.2) 0.580
12 76.6 (6.7) 59.5 (7.9) 0.213 62.5 (7.9) 73.6 (6.7) 0.724 73.8 (5.8) 79.4 (5.8) 0.758
Treading beads p -value 18 81.7 (4.2) 72.9 (5.0) 0.922 75.5 (4.9) 79.1 (4.3) 0.049 81.8 (5.1) 81.5 (5.1) 0.216
24 80.3 (3.5) 69.1 (4.3) 0.546 73.1 (4.1) 76.4 (3.6) 0.041 80.9 (2.8) 79.7 (2.8) 0.123
overall 0.716 0.072 0.156
OSAS Quality grasp wrist 0 2.32 (0.26) 2.01 (0.31) 2.12 (0.31) 2.21 (0.260 2.16 (0.35) 2.49 (0.35)
6 2.43 (0.26) 2.51 (0.31) 0.219 2.94 (0.31) 2.00 (0.27) 0.003 2.60 (0.35) 2.26 (0.35) 0.114
Treading beads (1–5) SDD
0.65p -value
12 2.55 (0.26) 2.59 (0.31) 0.397 3.05 (0.31) 2.10 (0.26) 0.020 2.81 (0.35) 2.29 (0.35) 0.149
18 2.36 (0.26) 2.32 (0.31) 0.437 2.56 (0.31) 2.12 (0.27) 0.128 2.48 (0.35) 2.25 (0.35) 0.280
24 2.48 (0.26) 2.40 (0.32) 0.500 2.66 (0.31) 2.21 (0.27) 0.127 2.54 (0.35) 2.42 (0.35) 0.387
overall 0.542 0.028 0.464
OSAS Quality grasp wrist 0 2.26 (0.27) 2.16 (0.32) 2.29 (0.32) 2.13 (0.27) 2.10 (0.38) 2.41 (0.38)
6 2.49 (0.27) 2.27 (0.32) 0.665 2.98 (0.32) 1.79 (0.27) 0.001 2.75 (0.38) 2.23 (0.38) 0.059
Pop-Onz (1–5) SDD 0.55
p -value
12 2.50 (0.27) 2.49 (0.32) 0.802 3.10 (0.32) 1.89 (0.27) 0.000 3.01 (0.38) 2.00 (0.38) 0.028
18 2.33 (0.27) 2.69 (0.32) 0.164 2.94 (0.32) 2.08 (0.27) 0.032 2.51 (0.38) 2.16 (0.38) 0.175
24 2.32 (0.27) 2.37 (0.32) 0.385 2.61 (0.32) 2.08 (0.27) 0.043 2.28 (0.38) 2.36 (0.38) 0.315
overall 0.553 0.011 0.189
OSAS Quality hold wrist 0 2.44 (0.26) 2.23 ((0.31) 2.19 (0.31) 2.48 (0.26) 2.23 (0.34) 2.65 (0.34)
Treading beads (1–5) SDD
0.71 p -value
6 2.44 (0.26) 2.62 (0.32) 0.218 3.00 (0.31) 2.06 (0.27) 0.000 2.71 (0.34) 2.17 (0.34) 0.020
12 2.58 (0.26) 2.60 (0.31) 0.445 2.86 (0.31) 2.31 (0.26) 0.006 2.76 (0.34) 2.40 (0.34) 0.055
18 2.53 (0.26) 2.39 (0.32) 0.822 2.68 (0.31) 2.23 (0.27) 0.017 2.72 (0.34) 2.34 (0.34) 0.050
24 2.47 (0.26) 2.34 (0.32) 0.815 2.50 (0.31) 2.31 (0.27) 0.117 2.37 (0.34) 2.58 (0.34) 0.573
overall 0.728 0.003 0.086
OSAS Quality hold wrist 0 2.35 (0.27) 2.11 (0.31) 2.16 (0.31) 2.30 (0.27) 2.07 (0.36) 2.63 (0.36)
6 2.68 (0.27) 2.37 (0.32) 0.829 3.12 (0.31) 1.93 (0.27) 0.000 2.99 (0.36) 2.36 (0.36) 0.007Pop-Onz (1–5) SDD 0.87
p -value
12 2.62 (0.27) 2.45 (0.31) 0.781 2.94 (0.31) 2.13 (0.27) 0.001 2.87 (0.36) 2.37 (0.36) 0.010
18 2.33 (0.27) 2.65 (0.32) 0.051 2.77 (0.31) 2.21 (0.27) 0.014 2.33 (0.36) 2.34 (0.36) 0.198
24 2.34 (0.27) 2.24 (0.31) 0.605 2.37 (0.31) 2.20 (0.27) 0.271 2.13 (0.36) 2.55 (0.36) 0.735
overall 0.215 0.000 0.024












Table 5 Amount and Quality of use of grasp and hold wrist scores, tasks older age group
Follow-up
weeks
BITT BoNT-A BoNT-A additional effect








p-value BoNT-A + BITT BITT-only p-value
n = 16 n = 5 n = 12 n = 9 n = 9 n = 7
OSAS percentage of use
both hands
0 77.3 (2.4) 81.0 (4.3) 78.2 (3.0) 80.1 (3.5) 76.2 (3.3) 78.5 (3.7)
6 77.7 (2.4) 74.4 (4.7) 0.193 80.3 (3.1) 71.9 (3.8) 0.019 82.8 (3.3) 72.3 (3.7) 0.011
12 77.3 (2.4) 77.4 (4.3) 0.472 78.5 (3.0) 76.2 (3.5) 0.324 77.9 (3.3) 76.8 (3.7) 0.484
18 76.8 (2.4) 79.3 (4.7) 0.822 78.7 (3.1) 77.5 (3.8) 0.469 78.2 (3.3) 75.2 (3.7) 0.275Making a sandwich
p -value
24 75.8 (2.4) 76.7 (4.7) 0.602 79.6 (3.1) 72.8 (3.8) 0.050 79.3 (3.3) 72.2 (3.7) 0.057
overall 0.737 0.127 0.087
OSAS Quality grasp wrist 0 1.62 (0.19) 1.66 (0.34) 1.59 (0.24) 1.70 (0.27) 1.65 (0.25) 1.56 (0.28)
Making a sandwich (1–5)
SDD 0.55 p -value
6 1.71 (0.19) 1.83 (0.35) 0.732 1.79 (0.24) 1.75 (0.28) 0.434 1.82 (0.25) 1.56 (0.28) 0.471
12 1.51 (0.19) 1.79 (0.34) 0.315 1.67 (0.24) 1.62 (0.27) 0.399 1.57 (0.25) 1.43 (0.28) 0.841
18 1.66 (0.19) 1.91 (0.35) 0.423 1.76 (0.24) 1.81 (0.28) 0.756 1.70 (0.25) 1.61 (0.28) 0.983
24 1.64 (0.19) 1.75 (0.35) 0.823 1.75 (0.24) 1.64 (0.28) 0.279 1.81 (0.250 1.45 (0.28) 0.265
overall 0.846 0.814 0.746
OSAS Quality grasp wrist 0 1.71 (0.22) 1.77 (0.39) 1.82 (0.28) 1.66 (0.32) 1.93 (0.29) 1.45 (0.33)
6 2.02 (0.22) 2.35 (0.41) 0.435 2.50 (0.28) 1.87 (0.33) 0.081 2.38 (0.29) 1.65 (0.33) 0.362Construction small (1–5)
SDD 0.47 p -value
12 2.00 (0.22) 1.64 (0.39) 0.163 2.14 (0.28) 1.49 (0.32) 0.064 2.31 (0.29) 1.69 (0.33) 0.615
18 1.88 (0.22) 1.89 (0.41) 0.872 2.05 (0.28) 1.73 (0.33) 0.554 2.07 (0.29) 1.69 (0.33) 0.719
24 1.76 (0.22) 1.42 (0.41) 0.226 1.70 (0.28) 1.48 (0.33) 0.830 2.00 (0.30) 1.50 (0.33) 0.926
overall 0.192 0.207 0.747
OSAS Quality grasp wrist 0 1.47 (0.17) 1.53 (0.31) 1.47 (0.22) 1.53 (0.25) 1.52 (0.24) 1.41 (0.27)
6 1.64 (0.18) 2.09 (0.32) 0.130 2.12 (0.22) 1.61 (0.26) 0.010 1.90 (0.24) 1.38 (0.27) 0.107Construction large (1–5)
SDD 0.81 p -value
12 1.68 (0.17) 1.78 (0.31) 0.861 1.91 (0.22) 1.56 (0.250 0.086 1.90 (0.24) 1.45 (0.27) 0.242
18 1.72 (0.17) 1.48 (0.33) 0.455 1.63 (0.22) 1.58 (0.26) 0.716 1.77 (0.24) 1.65 (0.27) 0.957
24 1.50 (0.17) 1.11 (0.33) 0.352 1.46 (0.22) 1.15 (0.26) 0.341 1.73 (0.24) 1.24 (0.270 0.442
overall 0.084 0.026 0.169
OSAS Quality hold wrist 0 1.74 (0.19) 1.76 (0.34) 1.65 (0.24) 1.85 (0.27) 1.73 (0.25) 1.72 (0.28)
6 1.98 (0.19) 2.05 (0.36) 0.881 2.17 (0.24) 1.86 (0.29) 0.053 2.27 (0.25) 1.64 (0.28) 0.044Making a sandwich (1–5)
SDD 0.85 p -value
12 1.62 (0.19) 1.90 (0.34) 0.420 1.77 (0.24) 1.75 (0.27) 0.434 1.72 (0.25) 1.49 (0.28) 0.506
18 1.71 (0.19) 2.09 (0.36) 0.237 1.80 (0.24) 2.01 (0.29) 0.964 1.70 (0.25) 1.69 (0.28) 0.992
24 1.76 (0.19) 1.82 (0.35) 0.899 1.70 (0.24) 1.88 (0.28) 0.937 1.82 (0.25) 1.66 (0.28) 0.380












Table 5 Amount and Quality of use of grasp and hold wrist scores, tasks older age group (Continued)
OSAS Quality hold wrist 0 1.86 (0.22) 1.97 (0.40) 1.88 (0.28) 1.95 (0.32) 1.93 (0.30) 1.76 ((0.34)
6 2.08 (0.22) 2.37 (0.42) 0.628 2.54 (0.28) 1.90 (0.34) 0.021 2.44 (0.30) 1.71 (0.34) 0.078Construction small (1.5)
SDD 0.81 p -value
12 1.96 (0.22) 1.81 (0.40) 0.461 2.28 (0.28) 1.50 (0.32) 0.005 2.34 (0.30) 1.58 (0.34) 0.065
18 1.98 (0.22) 1.69 (0.42) 0.293 2.17 (0.28) 1.50 (0.34) 0.017 2.27 (0.30) 1.69 (0.34) 0.199
24 1.84 (0.22) 1.74 (0.42) 0.576 1.97 (0.28) 1.61 (0.34) 0.166 2.12 (0.30) 1.54 (0.34) 0.202
overall 0.576 0.037 0.351
OSAS Quality hold wrist 0 1.59 (0.18) 1.52 (0.32) 1.67 (0.22) 1.44 (0.26) 1.69 (0.26) 1.49 (0.29)
6 1.74 (0.18) 1.80 (0.34) 0.678 2.00 (0.23) 1.54 (0.28) 0.400 1.97 (0.26) 1.50 (0.30) 0.367Construction large (1–5)
SDD 0.58 p -value
12 1.62 (0.18) 1.67 (0.32) 0.699 1.92 (0.22) 1.36 (0.26) 0.202 1.86 (0.26) 1.39 (0.29) 0.368
18 1.89 (0.18) 1.30 (0.34) 0.104 1.77 (0.23) 1.42 (0.27) 0.663 2.04 (0.26) 1.74 (0.29) 0.729
24 1.49 (0.18) 1.36 (0.34) 0.845 1.52 (0.23) 1.32 (0.27) 0.892 1.65 (0.26) 1.31 (0.29) 0.646
overall 0.260 0.603 0.874












Table 6 COPM performance and satisfaction scores
Follow-up
weeks
BITT BoNT-A BoNT-A additional effect








p-value BoNT-A + BITT BITT-only p-value
n = 24 n = 11 n = 18 n = 17 n = 13 n = 11
COPM goal 1 performance
p -value
0 3.7 3.1 3.8 3.1 4.2 3.2
12 7.8 5.1 0.008 6.0 6.8 0.042 7.5 8.1 0.069
24 7.3 5.2 0.067 5.8 6.7 0.044 6.8 7.8 0.024
overall 0.024 0.065 0.058
COPM goal 1 satisfaction
p -value
0 4.4 4.0 4–7 3.7 4.8 4.0
12 8.5 5.6 0.007 6.6 7.6 0.019 7.9 9.1 0.031
24 7.9 5.8 0.099 6.3 7.4 0.023 7.0 8.8 0.020
overall 0.024 0.036 0.042
COPM goal 2 performance
p -value
0 3.7 3.5 4.1 3.1 4.2 3.1
12 7.7 4.8 0.000 6.3 6.2 0.207 7.8 7.5 0.299
24 7.5 5.9 0.101 7.2 6.2 0.970 8.0 6.9 0.954
overall 0.001 0.318 0.458
COPM goal 2 satisfaction
p -value
0 4.6 4.8 5.1 4.3 5.1 4.1
12 8.3 5.0 0.000 6.7 6.6 0.367 8.2 8.4 0.211
24 8.1 5.9 0.016 7.3 6.7 0.753 8.2 8.1 0.351
overall 0.001 0.430 0.389
COPM goal 3 performance
p -value
0 4.0 3.5 3.7 3.7 4.0 4.0
12 8.0 4.3 0.000 5.8 6.4 0.320 7.9 8.0 0.918
24 7.8 5.8 0.107 6.8 6.8 0.881 7.9 7.6 0.750
overall 0.000 0.525 0.884
COPM goal 3 satisfaction
p -value
0 4.5 4.6 4.9 4.2 4.7 4.3
12 8.5 4.8 0.001 6.2 7.0 0.137 8.2 8.7 0.361
24 8.0 5.2 0.002 6.5 6.7 0.287 8.0 8.0 0.656
overall 0.003 0.301 0.558












(baseline) to 0.50 (median; interquartile range, IQR 0 –
2), this is a significant difference. At 18 weeks the GAS
improved to 1 (IQR −0.25 – 1.25) and at 24 weeks the
GAS was 0 (IQR −0.25 – 1.25). The BoNT-A + BITT
group also improved, but to a lesser extent: at 12 weeks
to 0 (IQR −0.75 – 1.75), at 18 weeks to 0 (IQR −0.75 –
1.50) and at 24 weeks to 0 (IQR −1.0 – 0). The BoNT-
A-only group scored worse at all measurement sessions.
Discussion
In this study, which was set up as an RCT with a
factorial design, we investigated the effect of BoNT-
A in the upper extremity and/or BITT on bimanual
performance, measured with the AHA and the AK
questionnaire; on the amount and quality of use of
the affected limb in standardized, age appropriate,
bimanual tasks, measured with the OSAS; and on
goal achievement, measured with the COPM and
the, by video observation blinded, GAS score. Due to
disappointing participant enrolment, the design had
to be adapted to the parents’ preference for either
BoNT-A + BITT or just the BITT-only programme.
Limitations of this study are the small numbers with
unequal group sizes. Therefore, the original RCT be-
came a clinical study. Nevertheless consistent results
were found.
Group 
Fig. 3 GAS blind score at 18 weeks medians and interquartile ranges per treatment group. Group 1 = BoNT-A + BITT, 2 = BoNT-A-only, 3 = BITT-only,
4 = control. Kruskal Wallis test p 0.059
Group 
Fig. 2 GAS blind score at 12 weeks medians and interquartile ranges per treatment group. Group 1 = BoNT-A + BITT, 2 = BoNT-A-only, 3 = BITT-only,
4 = control. Kruskal Wallis test p 0.002
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Although the differences between the groups were not
significant, the children in the BITT group (and control
group with younger children) showed a positive effect
on the AHA score, which was our primary outcome
measurement, at 12 weeks. BITT has a significant posi-
tive effect on bimanual performance, measured with the
AK and on goal achievement, measured with the COPM
and the blinded GAS score, not only at 12 weeks, the
end of the therapy programme, but also later at 18 and
24 weeks. Task specific exercise clearly leads to
achievement of the goals set by the children themselves
and, to a lesser extent, to improvement in bimanual
performance. Improvement of functional unimanual
and bimanual grip strength by BITT [17] possibly sup-
ports this.
In our study BoNT-A seems to have a negative effect
on bimanual performance, measured with the AHA. The
no-BoNT-A and the BITT-only group AHA score in-
creased from 0 to 12 weeks, whereas the BoNT-A and
the BoNT-A + BITT AHA score did not. This is in
contradiction with the results of Ferrari et al., who found
a significant increase of the AHA raw scores at 3 months
in the BoNT-A group (n = 11) in a placebo controlled
trial of 27 children with uCP, aged 3 to 12 years old,
who all received goal directed therapy [26]. They stated
that children with the House functional score [27] 4 and
5 would possibly benefit most from BoNT-A combined
with goal directed therapy. These children are compar-
able with the children in our study. At 6 months both
groups showed equal improvement on the AHA in their
study. Another recent RCT investigating the effects of
repeated BoNT-A injections combined with OT and
splinting compared with OT alone in very young chil-
dren with uCP (median age 3y 1 month) showed that 6
out of 10 children of the BoNT-A/OT group (n = 10) im-
proved ≥ 5u on the AHA at 12 months compared with 1
out of 10 in the OT group (n = 10) [28]. This study con-
cerns very young children with a lower House functional
score (1 – 3) but a similar degree of severity of impair-
ment according to the Zancolli grade. Olesch et al. who
studied also very young children, did not found a posi-
tive effect of additional BoNT-A on the activity level,
measured with the QUEST, but they found positive ef-
fects on the GAS [7].
In our study, BoNT-A had a negative effect in achiev-
ing the first COPM goal and at the GAS score. In the
study of Ferrari et al.[26] goal achievement with the
GAS was significantly better in the BoNT-A group,
whereas in the study of Lidman et al. [28] there was no
significant difference between the study groups in im-
provement on the COPM.
With the OSAS we found that BoNT-A has a positive
effect on the amount of use of the affected hand; espe-
cially during the time it works at 6 weeks in the
sandwich-making task, but also later on in the beading
task in the younger age group. The grasp finger score in
the BoNT-A group of the sandwich-making task showed
significantly more improvement at 6 weeks when com-
paring BoNT-A to no-BoNT-A. This is consistent with
the increase in the amount of use in this task at 6 weeks
and the fact that BoNT-A was injected in the thumb ad-
ductor, leading to improved thumb abduction, which is
necessary for this task. BoNT-A injections in the wrist
and finger flexors led to a significantly improved wrist
position in the quality of grasp and hold wrist scores in
several tasks, due to the effect of tone reduction of the
wrist and finger flexors, during the working time at 6
and 12 weeks in the older age group. In the younger
children this effect lasted even longer. Given that the
known smallest detectable differences of the quality of
grasp and hold wrist scores in these tasks vary from 0.34
to 0.87, the found differences are substantial [18].
Our OSAS results of improvement of wrist position
and thumb abduction after BoNT-A are in agreement
with the positive effect of BoNT-A and OT, compared to
OT alone, found in two reviews [1, 8] at 3 months on
the MUUL and the QUEST, as these instruments meas-
ure also quality of movement, wrist position and fluency.
Improvement at the GAS score by BoNT-A +OT was
also reported in these reviews and in the study of Ferrari
et al. [26] The GAS T-score of several goals used in the
studies in the reviews was not blinded. This may have
biased their results because in contrast, in our study a
negative additional effect of BoNT-A on the GAS score
was found. Here, trained OTsts scored the GAS on a
videotape of the main goal; unaware at which measure-
ment session the videotape was taken. Although in this
study the children who received BoNT-A improved also
at the COPM, the improvement was clearly less than in
the children who did not receive BoNT-A or those who
received BITT-only. As the study of Ferrari et al. [26]
was a placebo controlled RCT, their positive findings on
the GAS of BoNT-A speak against our results. However,
they discussed the importance of the individualised goal
directed therapy and goal setting, because also the pla-
cebo group achieved their goals.
Conlusions
In conclusion, BoNT-A has a positive effect on the qual-
ity of movement and amount of use of the affected UE
especially during the expected working time and some-
what longer in younger children. Contrary to other stud-
ies, we found no additional effect of BoNT-A on
bimanual performance and goal achievement. BITT on
the other hand, has a clear positive effect on goal
achievement and bimanual performance. To improve bi-
manual performance and goal achievement in children
with spastic uCP who are able to actively open their
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hand, intensive task specific bimanual training is, in our
opinion, the first choice of treatment. In children aged
6 years or younger with severe spasticity of the affected
hand leading to limited functional hand use, additional
BoNT-A injections are to be considered.
Additional files
Additional file 1: AHA unit-scores per child and BoNT-A dose in
units per child. (DOCX 18 kb)
Additional file 2: Characteristics and outcome measures at baseline
younger age group 2.5–6 years old. (DOC 48 kb)
Additional file 3: Characteristics and outcome measures at baseline
older age group 7–12 years old. (DOC 53 kb)
Competing interests
The authors declare that they have no competing interests. Although the
Dysport® vials were provided by Ipsen, the study design was made
independently by the author group.
Authors’ contributions
LS is first corresponding author and participated in drafting the manuscript.
She made main contributions to design, acquisition, analysis and interpretation
of data. YJ and BW have been involved in drafting the manuscript, analysis and
interpretation of data and critically revising it. ER and AD were involved in data
acquisition and development of the OSAS. JB was involved in development of
the study protocol and including the patients for this study. RS and HV critically
revised the intellectual content of the article. All authors red and approved the
final manuscript.
Acknowledgements
This study was supported by grants provided by Johanna Kinderfonds,
Stichting Rotterdams Kinderrevalidatie Fonds Adriaanstichting, Phelps
Stichting, Profileringsfonds azM, Elisabeth Strouven Stichting, Kanunnik
Salden-Nieuwenhof Stichting, and Adelante.
The Dysport® vials were provided by Ipsen.
Author details
1Adelante, Paediatric Rehabilitation, Onderstestraat 29, 6301 KA, Valkenburg,
The Netherlands. 2Adelante, Centre of Expertise in Rehabilitation and
Audiology, Zandbergsweg 111, 6432 CC, Hoensbroek, The Netherlands.
3Department of Rehabilitation Medicine, Maastricht University, Research
School CAPHRI, PO Box 6166200 MD, Maastricht, The Netherlands.
4Department of Methodology and Statistics, Maastricht University, Research
School CAPHRI, Maastricht, The Netherlands. 5Department of Rehabilitation
Medicine, Free University Medical Centre, De Boelelaan 1118, 1081 HZ,
Amsterdam, The Netherlands. 6Department of Rehabilitation Medicine,
Maastricht University Medical Centre, PO Box 52006202 AZ, Maastricht, The
Netherlands. 7Department of Neurology, Maastricht University Medical
Centre, Maastricht, The Netherlands. 8Department of Neurology, Maastricht
University, Research School GROW, Maastricht, The Netherlands.
Received: 20 January 2015 Accepted: 12 August 2015
References
1. Hoare BJ, Wallen MA, Imms C, Villanueva E, Rawicki HB, Carey L. Botulinum
toxin A as an adjunct to treatment in the management of the upper limb
in children with spastic cerebral palsy (UPDATE). Cochrane Database Syst
Rev. 2010;1:CD003469. Review.
2. Randall M, Carlin JB, Chondros P, Reddihough D. Reliability of the
Melbourne assessment of unilateral upper limb function. Dev Med Child
Neurol. 2001;43:761–7.
3. DeMatteo C, Law M, Russell D, Pollock N, Rosenbaum P, Walter S. The
Reliability and Validity of the Quality of Upper Extremity Skills Test. Phys Occ
Ther Pediatrics. 1993;13(2):1–18.
4. Feldman AB, Haley SM, Coryell J. Concurrent and construct validity of the
Pediatric Evaluation of Disability Inventory. Phys Ther. 1990;10:602–10.
5. Steenbeek D, Ketelaar M, Galama K, Gorter JW. Goal attainment scaling in
paediatric rehabilitation: a critical review of the literature. Dev Med Child
Neurol. 2007;49(7):550–6.
6. Verkerk GJ, Wolf MJ, Louwers AM, Meester-Delver A, Nollet F. The
reproducibility and validity of the Canadian Occupational Performance
Measure in parents of children with disabilities. Clin Rehabil.
2006;20(11):980–8.
7. Olesch CA, Greaves S, Imms C, Reid SM, Graham HK. Repeat botulinum
toxin-A injections in the upper limb of children with hemiplegia: a
randomized controlled trial. Dev Med Child Neurol. 2010;52:79–86.
8. Sakzewski L, Ziviani J, Boyd RN. Efficacy of upper limb therapies for
unilateral cerebral palsy: a meta-analysis. Pediatrics. 2014;133(1):e175–204.
9. Elvrum AK, Brændvik SM, Sæther R, Lamvik T. Effectiveness of resistance training
in combination with botulinum toxin-A on hand and arm use in children with
cerebral palsy: a pre-post intervention study. BMC Pediatr. 2012;12:91.
10. Novak I, McIntyre S, Morgan C, Campbell L, Dark L, Morton N, et al. A
systematic review of interventions for children with cerebral palsy: state of
the evidence. Dev Med Child Neurol. 2013;55(10):885–910.
11. Hoare B, Imms C, Villanueva E, Rawicki HB, Mattyas T, Carey L. Intensive
therapy following upper limb botulinum toxin A injection in young children
with unilateral cerebral palsy: a randomized trial. Dev Med Child Neurol.
2013;55:238–47.
12. Krumlinde-Sundholm L, Eliasson A. Development of the Assisting Hand
Assessment: A Rasch-built measure intended for children with unilateral
upper limb impairments. Scand J Occup Ther. 2003;10:16–26.
13. Krumlinde-Sundholm L, Holmefur M, Kottorp A, Eliasson A-C. The Assisting
Hand Assessment: current evidence of validity, reliability, and
responsiveness to change. Dev Med Child Neurol. 2007;49:259–64.
14. Gordon AM, Hung YC, Brandao M, Ferre CL, Kuo HC, Friel K, et al. Bimanual
Training and Constraint-Induced Movement Therapy in Children With
Hemiplegic Cerebral Palsy: A Randomized Trial. Neurorehabil Neural Repair.
2011;25:692–702.
15. Sakzewski L, Ziviani J, Abbott JF, Macdonell RA, Jackson GD, Boyd RN.
Randomized trial of constraint-induced movement therapy and bimanual
training on activity outcomes for children with congenital hemiplegia. Dev
Med Child Neurol. 2011;53:313–20.
16. Deppe W, Thuemmler K, Fleischer J, Berger C, Meyer S, Wiedemann B.
Modified constraint-induced movement therapy versus intensive bimanual
training for children with hemiplegia – a randomized controlled trial. Clin
Rehabil. 2013;27(10):909–20.
17. Speth L, Janssen-Potten Y, Leffers P, Rameckers E, Defesche A, Winkens B,
et al. Effects of botulinum toxin A and/or bimanual task-oriented therapy on
upper extremity impairments in unilateral Cerebral Palsy: an explorative
study. Eur J Paediatr Neurol. 2015;19(3):337–48.
18. Speth L, Janssen-Potten Y, Leffers P, Rameckers E, Defesche A, Geers R, et al.
Observational skills assessment score: reliability in measuring amount and
quality of use of the affected hand in unilateral cerebral palsy. BMC Neurol.
2013;13:152.
19. Arnould CPM, Renders A, Thonnard JL. ABILHAND-Kids: a measure of
manual ability in children with cerebral palsy. Neurology. 2004;63:1045–52.
20. Schulz KF, Altman DG, Moher D. CONSORT2010 Statement: Updated
Guidelines for Reporting Parallel Group Randomized Trials. Ann Intern Med.
2010;152(11):1–8.
21. Eliasson AC, Krumlinde-Sundholm L, Rosblad B, Beckung E, Arner M, Ohrvall
AM, et al. The Manual Ability Classification System (MACS) for children with
Cerebral Palsy: scale development and evidence of validity and reliability.
Dev Med Child Neurol. 2006;48:549–54.
22. Zancolli EA, Zancolli Jr E. Surgical rehabilitation of the spastic upper limb in
cerebral palsy. In: Lamb DW, editor. The Paralyzed Hand. Edinburgh:
Churchill Livingstone; 1987. p. 153–60.
23. Heinen F, Desloovere K, Schroeder AS, Berweck S, Borggraefe I,
van Campenhout A, et al. The updated European Consensus 2009 on the
use of Botulinum toxin children with cerebral palsy. Eur J Paediatric Neurol.
2010;14(1):45–66.
24. Eliasson AC, Krumlinde-sundholm L, Shaw K, Wang C. Effects of constraint-
induced movement therapy in young children with hemiplegic cerebral
palsy: an adapted model. Dev Med Child Neurol. 2005;47:266–75.
25. Turner-Stokes L. Goal attainment scaling (GAS) in rehabilitation: a practical
guide. Clin Rehabil. 2009;23:362–70.
Speth et al. BMC Neurology  (2015) 15:143 Page 14 of 15
26. Ferrari A, Maoret AR, Muzzini S, Alboresi S, Lombardi F, Sgandurra G, et al.
A randomized trial of upper limb botulinum toxin versus placebo injection,
combined with physiotherapy, in children with hemiplegia. Res Dev Disabil.
2014;35(10):2505–13.
27. House JH, Gwathmey FW, Fidler MO. A dynamic approach to the thumb-in-
palm deformity in cerebral palsy. J Bone Joint Surg. 1981;63(2):216–25.
28. Lidman G, Nachmeson A, Peny-Dahlstrand M, Himmelmann K. Botulinum
toxin A injections and occupational therapy in children with unilateral
spastic cerebral palsy: a randomized controlled trial. Dev Med Child Neurol.
2015;57(8):754–61.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Speth et al. BMC Neurology  (2015) 15:143 Page 15 of 15
